EUCTR2014-001558-40-HU进行中（未招募）不适用
Expanded Access Study of MEK162 in Metastatic or Unresectable NRAS Mutation-positive Melanoma
zsoki Hospital0 个研究点开始时间: 2014年4月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients eligible for inclusion in this Treatment Plan have to meet all of the following criteria:
- •Written informed consent must be obtained prior to any screening procedures or treatment assignment.
- •1. Signed written informed consent;
- •2. Male or female patient, age = 18 years;
- •3. Histologically confirmed diagnosis of locally advanced, unressectable or metastatic cutaneous melanoma AJCC Stage IIIC or IV;
- •4. Presence of activating mutations of RAS oncogenes in tumor tissue prior to randomization as determined by a validated method.
- •5. Adequate bone marrow, organ function and laboratory parameters:
- •Absolute neutrophil count (ANC) = 1.5 x 109/L,
- •Hemoglobin (Hgb) = 10 g/dL without transfusions,
- •Platelets (PLT) = 100 x 109/L without transfusions,
- •AST and/or ALT = 2.5 × upper limit of normal (ULN); patient with liver metastases = 5 ×ULN,
- •Total bilirubin = 2 × ULN,
- •Creatinine = 1.5 mg/dL;
- •6. Adequate cardiac function:
- •left ventricular ejection fraction (LVEF) = 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram,
- •QTc interval = 480 ms;
- •7. Able to take oral medications;
- •8. Patient is deemed by the Investigator to have the initiative and means to be compliant with the treatment plan (treatment and follow-up requested by the treating physician);
- •9. Negative serum ß HCG test (female patient of childbearing potential only) performed locally within 72 hours prior to first dose.
- •10. Has failed available standard of care treatment options or is highly unlikely, due to their disease characteristics, to respond to the available standard of care treatment options.
- •11. Is not eligible for participation in any MEK162 ongoing clinical trials or has recently completed a clinical trial that has been terminated and, after considering other options (e.g., trial extensions, amendments, etc.), the clinical team has determined that treatment is necessary and there are no other feasible alternatives for the patient
- •12. Is not being transferred from an ongoing clinical trial for which they are still eligible
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Patients eligible for this Treatment Plan must not meet any of the following criteria:
- •1. History of hypersensitivity to any drugs or metabolites of similar chemical classes as MEK162.
- •2. Any active central nervous system (CNS) lesion (i.e., those with radiographically unstable, symptomatic lesions). However, patient treated with stereotactic radiotherapy, surgery or whole-brain radiation are eligible if the patient remained without evidence of CNS disease progression = 3 months. Patients must be off corticosteroid therapy for = 3 weeks;
- •3. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes);
- •4. History of retinal degenerative disease;
- •5. History of Gilbert’s syndrome;
- •6. Previous or concurrent malignancy with the following exceptions:
- •adequately treated basal cell or squamous cell carcinoma of the skin (adequate wound healing is required prior to study entry),
- •in situ carcinoma of the cervix, treated curatively and without evidence of recurrence for at least 3 years prior to the study,
- •a primary malignancy which has been completely resected and is in complete remission for =5 years;
- •7. Prior therapy with a MEK- inhibitor;
- •8. Concomitant use of any anticancer agent (chemotherapy, immunotherapy or targeted agents);
- •9. Prior participation during the NEMO Study (even if the patient was randomized to receive DTIC);
- •10. Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following:
- •History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) <6 months prior to screening,
- •Symptomatic chronic heart failure; evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities < 6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia;
- •11. Uncontrolled arterial hypertension despite appropriate medical therapy;
- •12. Known positive serology for HIV, active hepatitis B, and/or active hepatitis C infection;
- •13. Patients who have neuromuscular disorders that are associated with elevated CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy);
- •14. Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment. NB: Muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK162 treatment;
- •15. Impairment of gastrointestinal function or gastrointestinal disease (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection);
- •16. Any other condition that would, in the treating physician’s judgment, contraindicate the patient’s participation in this compassionate use program due to safety concerns or compliance with treatment procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc.;
- •17. Patients who have undergone major surgery = 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure;
- •18. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed b
研究者
相似试验
招募中
2 期
A Study of MEK162 in NRAS mutated metastatic melanoma patients with brain metastasesC43Malignant melanoma of skinDRKS00009626niversitätsSpital ZürichDermatologische KlinikSwitzerland25
终止
1 期
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Recurrent Adult Acute Myeloid LeukemiaNCT02049801Bruno C. Medeiros1
已完成
2 期
MEK162 for Patients With RAS/RAF/MEK Activated TumorsSolid Tumor and Hematologic MalignanciesNCT01885195Pfizer110
进行中（未招募）
1 期
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)Gastrointestinal Stromal Tumor (GIST)NCT01991379Memorial Sloan Kettering Cancer Center75
进行中（未招募）
1 期
MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable NRAS Melanoma: A Phase Ib/II Trial of Trametinib plus Hydroxychloroquine in Patients with NRAS Melanoma. CHLORO TRAM MEEUCTR2019-001399-13-FRHospices Civils de Lyon29